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Abstract
Background: Dystroglycanopathies are a clinically and genetically heterogeneous group of disorders that are
typically characterised by limb-girdle muscle weakness. Mutations in 18 different genes have been associated with
dystroglycanopathies, the encoded proteins of which typically modulate the binding of α-dystroglycan to extracellular
matrix ligands by altering its glycosylation. This results in a disruption of the structural integrity of the myocyte, ultimately
leading to muscle degeneration.
Methods: Deep phenotypic information was gathered using the PhenoTips online software for 1001 patients with
unexplained limb-girdle muscle weakness from 43 different centres across 21 European and Middle Eastern countries.
Whole-exome sequencing with at least 250 ng DNA was completed using an Illumina exome capture and a 38 Mb
baited target. Genes known to be associated with dystroglycanopathies were analysed for disease-causing variants.
Results: Suspected pathogenic variants were detected in DPM3, ISPD, POMT1 and FKTN in one patient each, in POMK in
two patients, in GMPPB in three patients, in FKRP in eight patients and in POMT2 in ten patients. This indicated a
frequency of 2.7% for the disease group within the cohort of 1001 patients with unexplained limb-girdle muscle
weakness. The phenotypes of the 27 patients were highly variable, yet with a fundamental presentation of proximal
muscle weakness and elevated serum creatine kinase.
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Conclusions: Overall, we have identified 27 patients with suspected pathogenic variants in dystroglycanopathy-
associated genes. We present evidence for the genetic and phenotypic diversity of the dystroglycanopathies as a
disease group, while also highlighting the advantage of incorporating next-generation sequencing into the diagnostic
pathway of rare diseases.
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Background
DAG1 (dystroglycan 1) is a 5.8 kb gene transcript on
chromosome 3p21 that is widely expressed in human tis-
sue, including in the skeletal muscle [1]. The protein
undergoes N- and O-linked glycosylation and is
post-transcriptionally cleaved into two mature subunits:
the ~ 156 kDa secreted cell surface α-dystroglycan and the
43 kDa transmembrane β-dystroglycan [2]. The dystrogly-
can complex, composed of one α- and one β-subunit, is a
component of the larger dystrophin-glycoprotein complex
that links the subsarcolemmal actin cytoskeleton to the
extracellular matrix (ECM) [3]. ECM ligands such as lam-
inin strictly rely on the correct presentation of glycan
structures on the surface of α-dystroglycan for binding [4],
and without this precise glycosylation, the function and
integrity of the muscle cell are compromised.
Alpha-dystroglycan is glycosylated by a series of tightly
regulated proteins as it is processed from the nucleus,
through the endoplasmic reticulum and Golgi apparatus
to reach the cell surface [5, 6]. Mutations in any of the
genes encoding these proteins could result in diminished
protein function, aberrant α-dystroglycan glycosylation
and thus a reduced capacity to bind ECM ligands [7].
The disorders associated with abnormal α-dystroglycan
glycosylation are collectively known as dystroglycanopa-
thies. The clinical manifestations of dystroglycanopathies
are extremely variable with a spectrum of severity within
the disease group [8, 9]. Severe dystroglycanopathies are
congenital and result in structural brain, eye and muscle
abnormalities such as Walker-Warburg syndrome [10],
muscle-eye-brain disease [11] and Fukuyama muscular
dystrophy [12]. The spectrum then ranges through to
limb-girdle muscular dystrophies (LGMD), which consti-
tute less severe forms of the disease group with an adult
onset and no brain or eye abnormalities [13, 14].
Homozygous and compound heterozygous mutations
in 17 genes, plus DAG1 itself, have been associated with
dystroglycanopathies [15]. The encoded proteins include
those with well-defined glycosyltransferase functions as
well as those with less well-characterised functions
(Table 1). In addition to researching those already
known to be associated with dystroglycanopathies, an-
other challenge is to identify additional proteins in the
glycosylation pathway that underlie disease pathology.
For example, it is estimated that 20–50% of suspected
dystroglycanopathy patients do not harbour mutations
in characterised dystroglycanopathy genes, suggesting
the genetic cause of the disease is currently unknown for
approximately half of patients. With such genetic and
clinical heterogeneity among dystroglycanopathies, the
causative genes can be difficult to determine from the
phenotypes alone.
Next-generation sequencing (NGS) is a well-developed
methodology that can benefit the understanding, charac-
terisation and diagnosis of such rare neuromuscular dis-
eases. The entire exome of a patient can be sequenced,
known as whole-exome sequencing (WES), at rapidly
declining costs. Immediately performing WES could
negate the need for undirected preliminary molecular in-
vestigations that can inflate the costs of a diagnostic
evaluation [16]. MYO-SEQ is a research collaboration
between academia, patient organisations and industry.
This project applies WES to patients with unexplained
limb-girdle muscle weakness and targets the analysis to-
wards genes with a known association to neuromuscular
diseases. Included in the candidate gene list were those
involved in the glycosylation of α-dystroglycan. Here, we
present the identification of 27 patients with putative
pathogenic variants in dystroglycanopathy-associated
genes from the targeted WES analysis of 1001 patients
with unexplained limb-girdle muscle weakness. We
highlight the diversity of the disease group and offer fur-
ther characterisations of the diseases at the milder,
limb-girdle weakness end of the spectrum.
Methods
Patients
Ethical approval (REC reference number 08/H0906/28)
was granted by the Newcastle and North Tyneside
Research Ethics Committee. One thousand and one pa-
tients were recruited throughout Europe and neighbour-
ing countries, and informed written consent was given
by all. Inclusion criteria stipulated that patients must
present with limb-girdle muscle weakness and/or ele-
vated serum creatine kinase (CK) activity.
Whole-exome sequencing and data analysis
WES and data processing were performed by the
MacArthur laboratory at the Broad Institute of MIT and
Harvard (Broad Institute, Cambridge, MA, USA) as
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detailed previously [17]. The variant call set was
uploaded onto the MacArthur laboratory’s seqr platform
for genomic data analysis. The biological relevance of
the detected variants was determined by considering the
(i) ClinVar reports of pathogenicity [18], (ii) published
literature, (iii) population frequency detailed by the gno-
mAD reference population database from the Broad In-
stitute that contains exome data from over 120,000
individuals [19] and (iv) deleteriousness of the variant
predicted by PolyPhen-2 [20], SIFT [21], MutationTa-
ster2 [22] and FATHMM [23]. The detected variants
were matched to the patient’s phenotype, and those that
were most likely to be disease-causing were reported
back to the referring clinician.
Muscle histopathology
Muscle biopsies were obtained for all patients and ana-
lysed following standard histological techniques for light
microscopy by local pathologists. Biopsy reports from
pathology departments formed the basis to describe
histological features in our patient cohort. Immunostain-
ing was performed for 21 patients. The primary
anti-α-dystroglycan antibodies that were used were
VIA4-1 and IIH6C4 (Millipore), and NBP2-14868
Table 1 Genes associated with dystroglycanopathies
Gene Protein function Associated dystroglycanopathy according to OMIM [49] Reference
B3GALNT2 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 11, with brain and eye anomalies [50]
B3GNT1 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 13, with brain and eye anomalies [51]
DAG1 Connects actin cytoskeleton
to extracellular matrix
Congenital muscular dystrophy-dystroglycanopathy type A 9, with brain and eye anomalies [52]
Limb-girdle muscular dystrophy-dystroglycanopathy type C 9 [53]
DOLK Kinase Congenital disorder of glycosylation type Im [54]
DPM1 Transferase Congenital disorder of glycosylation type Ie [55]
DPM2 Transferase Congenital disorder of glycosylation type Iu [56]
DPM3 Transferase Congenital disorder of glycosylation type Io [44]
FKRP Glycosyltransferase Limb-girdle muscular dystrophy-dystroglycanopathy type C 5/LGMD2I [25]
Congenital muscular dystrophy-dystroglycanopathy type A 5, with or without mental retardation [57]
Congenital muscular dystrophy-dystroglycanopathy type B 5, with or without mental retardation [25]
FKTN Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 4, with brain and eye anomalies [58]
Congenital muscular dystrophy-dystroglycanopathy type B 4, without mental retardation [28]
Limb-girdle muscular dystrophy-dystroglycanopathy type C 4 [59]
GMPPB Transferase Congenital muscular dystrophy-dystroglycanopathy type A 14, with brain and eye anomalies [30]
Congenital muscular dystrophy-dystroglycanopathy type B 14, with mental retardation
Limb-girdle muscular dystrophy-dystroglycanopathy type C 14
ISPD Synthase Congenital muscular dystrophy-dystroglycanopathy type A 7, with brain and eye anomalies [47]
Limb-girdle muscular dystrophy-dystroglycanopathy type C 7 [60]
LARGE1 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type B 6, with mental retardation [61]
POMGNT1 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 3, with brain and eye anomalies [62]
Congenital muscular dystrophy-dystroglycanopathy type B 3, with mental retardation [28]
Limb-girdle muscular dystrophy-dystroglycanopathy type C 3 [63]
POMGNT2 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 8, with brain and eye anomalies [64]
POMK Kinase Congenital muscular dystrophy-dystroglycanopathy type A 12, with brain and eye anomalies [65]
Limb-girdle muscular dystrophy-dystroglycanopathy type C 12 [66]
POMT1 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 1, with brain and eye anomalies [67]
Congenital muscular dystrophy-dystroglycanopathy type B 1, with mental retardation [68]
Limb-girdle muscular dystrophy-dystroglycanopathy type C 1 [69]
POMT2 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 2, with brain and eye anomalies [29]
Congenital muscular dystrophy-dystroglycanopathy type B 2, with mental retardation
Limb-girdle muscular dystrophy-dystroglycanopathy type C 2
TMEM5 Glycosyltransferase Congenital muscular dystrophy-dystroglycanopathy type A 10, with brain and eye anomalies [45]
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(Novus Biologicals) for patients 6 and 7 only. The tech-
niques used for patients 9, 10, 13 and 23 were unknown.
Results
Homozygous variants within dystroglycanopathy-associated
genes
Dystroglycanopathies have so far only been reported
with an autosomal recessive pattern of inheritance, and
so only homozygous or compound heterozygous muta-
tions in the associated genes could result in the disease
phenotype, while heterozygous carriers are not affected
by muscle disease. Of the 1001 patients (46% female,
54% male, mean age 39 years, median age 38 years, age
range 2 to 88 years) whose exomes were analysed, nine
patients had suspected pathogenic homozygous variants
that could account for their clinical presentations
(Table 2). Patient 1 had a rare homozygous missense
variant in DPM3 (p.Leu44Pro) that is absent in homozy-
gosity in the control population and that affects a highly
conserved amino acid [24]. At the age of 30 years, he
presented with, and fully recovered from, an asymmetric
brachial plexopathy (serum creatine kinase [CK] activity
of 4310 IU/L [normal < 200 IU/L]). Twelve years later,
he displayed an unsteady gait (serum CK levels of
2732 IU/L), and a proximal lower limb weakness mildly
progressed over the course of the next 5 years. Patients
2–8 had homozygous missense variants in FKRP
(p.Leu276Ile for all but patient 3 who instead had a
p.Tyr182His change) [25], with a young age at disease
onset, proximal muscle weakness and an elevated serum
CK activity. Patient 7 first presented with muscle cramps
on exercise. Patient 22 had a novel homozygous missense
variant in POMT2 (p.Gly238Val) [26], with an onset in
childhood of proximal upper and lower limb weakness,
central and cortical atrophy and spinal rigidity.
Compound heterozygous variants within
dystroglycanopathy-associated genes
An additional 18 patients had suspected pathogenic com-
pound heterozygous variants in dystroglycanopathy-asso-
ciated genes (Table 3). Patient 9 harboured variants in
FKRP (p.Leu276Ile and p.Pro462Ser) [25, 27] and had a
largely similar phenotype to the homozygous FKRP pa-
tients. Patient 10 carried variants in FKTN (p.Arg307Ter
and p.Arg307Gln) [28, 29], with infantile onset,
limb-girdle weakness and elevated serum CK activity.
Patients 11 and 12 harboured variants in GMPPB
(p.Asp27His and p.Arg287Trp) [30, 31]. Patient 13 simi-
larly carried the p.Asp27His missense variant in GMPPB
[30], but instead, this occurred in combination with a
novel frameshift variant (p.Met64Ter). All three patients
had an onset of symptoms at a young age and a slowly
progressive disease course. Patient 14 harboured variants
in ISPD (p.Cys56ValfsTer60 and p.Ser202Leu), presenting
with a slowly progressive limb-girdle muscle weakness
phenotype, with both an EMG and a muscle biopsy dis-
playing myopathic changes and an elevated serum CK ac-
tivity. Onset was in young adulthood, and there were no
ocular or cognitive impairments. Patients 15 and 16 were
siblings from non-consanguineous parents who presented
during childhood with muscle cramps, hyperlordosis, calf
pseudohypertrophy, scapular winging and elevated serum
Table 2 Suspected pathogenic homozygous variants detected by the MYO-SEQ project in dystroglycanopathy-associated genes
Patient Gene Location Predicted deleteriousness ClinVar clinical
significance
gnomAD
allele
frequency
hg19
co-ordinates
Protein
change
Sequence
change
SIFT PolyPhen-2 MutationTaster2 FATHMM
1 DPM3 chr1:155112676 p.Leu44Pro c.131T>C Damaging Probably
damaging
Disease causing Tolerated No 0.000016a
2 FKRP chr19:47259533 p.Leu276Ile c.826C>A Tolerated Benign Disease causing Damaging Pathogenic;
likely pathogenic
0.001089a
3 FKRP chr19:47259251 p.Tyr182His c.544T>C – Probably
damaging
Disease causing Damaging Uncertain 0.000018a
4 FKRP chr19:47259533 p.Leu276Ile c.826C>A Tolerated Benign Disease causing Damaging Pathogenic;
likely pathogenic
0.001089a
5 FKRP chr19:47259533 p.Leu276Ile c.826C>A Tolerated Benign Disease causing Damaging Pathogenic;
likely pathogenic
0.001089a
6 FKRP chr19:47259533 p.Leu276Ile c.826C>A Tolerated Benign Disease causing Damaging Pathogenic;
likely pathogenic
0.001089a
7 FKRP chr19:47259533 p.Leu276Ile c.826C>A Tolerated Benign Disease causing Damaging Pathogenic;
likely pathogenic
0.001089a
8 FKRP chr19:47259533 p.Leu276Ile c.826C>A Tolerated Benign Disease causing Damaging Pathogenic;
likely pathogenic
0.001089a
22 POMT2 chr14:77767536 p.Gly238Val c.713G>T Tolerated Possibly
damaging
Disease causing Damaging Uncertain 0.000000a
aNot reported in homozygosity in gnomAD
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CK activity [32]. They carried rare variants in POMK
(p.Pro322Leu and p.Arg46Ter). Patient 17 carried a rare
missense variant in POMT1 (p.Pro66Leu) in addition to a
frameshift variant (p.Asp723GlyfsTer8) [33]. He had a
non-progressive disease course from infancy with
limb-girdle weakness; he did not have any contractures or
spinal rigidity. Patients 19–21 and patients 23–27 all har-
boured previously unreported variants in POMT2, seven
of which were absent in the control population. Patient 23
carried novel frameshift (p.Gly705GlufsTer31) and mis-
sense (p.Thr184Met) [34] variants in POMT2, while pa-
tient 24 harboured two missense variants in the gene
(p.Tyr666Cys and p.Tyr136His) [35]. A summary of the
glycosylation pathway and the localisation of the associ-
ated proteins is depicted in Fig. 1.
Patient phenotypes
Overall, the 27 patients (18 compound heterozygotes
and nine homozygotes) had an average age of 32 years
(age range 11 to 63 years, median age 28 years), with 15
females (56%) and 12 males (44%) in the cohort. All
patients had limb-girdle muscle weakness and an ele-
vated serum CK activity (Additional file 1). The age of
disease onset ranged from foetal to middle age, and
while the majority of patients had a progressive disease,
three patients had non-progressive symptoms.
Forty-four percent of the 27 patients were unable to
walk independently at the time of enrolment onto the
project. Eighteen patients had normal cognitive capabil-
ities; nine had reported cognitive impairment. Patients
13, 15 and 24 had slight valve defects, left ventricular en-
largement and dilated cardiomyopathy, respectively,
while patient 23 had a reduced left ventricular fractional
shortening (LVFS) of 25%. The cardiac work-ups for the
remaining patients were unremarkable. Fourteen pa-
tients had reduced forced vital capacities (FVC) ranging
between 34 and 83%. Muscle imaging scans were avail-
able for 21 patients, four of which were unremarkable.
The imaging for the remaining patients showed fatty re-
placement primarily of the paraspinal and proximal mus-
cles of the lower limbs. Electromyography (EMG) results
displayed a predominantly myopathic pattern, while
Fig. 1 Localisation of the proteins involved in the glycosylation of α-dystroglycan. Only the encoded proteins of the genes identified as harbouring
suspected pathogenic variants in the MYO-SEQ project are shown. DAG1 is transcribed and translated into α-dystroglycan and β-dystroglycan subunits.
As the proteins are processed through the endoplasmic reticulum and Golgi body to the muscle cell membrane (pathway indicated by grey arrows),
GMPPB, POMT1, POMT2, POMK, ISPD, DPM3, FKRP and fukutin all contribute to the correct glycosylation of the α-subunit. The glycosylation of
α-dystroglycan is required for interactions with extracellular matrix components; the dystroglycan complex as a whole thus acts as an anchor
between the extracellular matrix and the intercellular actin cytoskeleton
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muscle biopsies showed either myopathic and/or dys-
trophic changes. The biopsy of patient 6 showed internal
nuclei and that of patient 8 showed glycogen accumula-
tion. Immunohistochemistry (IHC) studies detected an
α-dystroglycan deficiency or reduced α-dystroglycan gly-
cosylation in 14 patients.
Discussion
Eighteen genes are currently known to be associated
with dystroglycanopathies, with more causal genes yet to
be identified [15]. The genes and their specific mutations
do not always correlate with the phenotype or its sever-
ity, meaning dystroglycanopathies are an inherently
complex group of neuromuscular diseases. Here, we
used an unbiased sequencing approach to investigate the
underlying genetic mechanisms of this disease group.
This was in the form of targeted WES, an NGS technol-
ogy that interrogates the 1% of the human genome that
is coding. As 85% of known pathogenic variants reside
in the coding regions alone [36], both the cost and the
analysis workload associated with a whole-genome se-
quencing approach were avoided. The success of WES is
widely recognised and has been reported in a range of
diseases such as Parkinson disease [37], autism [38] and
inflammatory bowel disease [39]. Indeed, we used tar-
geted WES analysis in 1001 patients with unexplained
limb-girdle muscle weakness and have found suspected
pathogenic variants in 27 (2.7%) patients across nine of
the 18 dystroglycanopathy-associated genes. The patients
did not harbour suspected or potentially pathogenic vari-
ants in any other of the 429 known neuromuscular disease
genes that were analysed as part of our study. The absence
of a unified international dystroglycanopathy registry
means that such contributions to rare disease research
may not be fully exploited, which would otherwise be ad-
vantageous in furthering current knowledge of the disease.
Despite the central presentation of proximal muscle
weakness, which was shared by all of our patients, we
did not observe a common, core phenotype that could
reliably distinguish the disease group from other
LGMDs. Phenotypic variability was high even within the
same disease group; for example, the reported age of dis-
ease onset for patients with POMT2 variants ranged
from foetal to middle age. POMT2 deficiency was ini-
tially associated with Walker-Warburg syndrome, a con-
genital disease with brain, eye and muscle affections
[40], while mutations in the gene were only later de-
scribed to be associated with LGMD2N [34]. This plei-
otropy could explain such phenotypic differences, where
perhaps the functional severity of the mutations corre-
lates with the extent of hypoglycosylation and thus the
severity of the resulting phenotype.
Indeed, a correlation between reduced α-dystroglycan
staining and clinical course was observed for patients
with mutations in POMT1, POMT2 and POMGNT1
[41]. In contrast, however, the study did not always de-
tect such a pattern for patients with mutations in FKTN
and FKRP. Within our own cohort, staining for
α-dystroglycan was performed for most of our patients,
yet an α-dystroglycan deficiency or reduced
α-dystroglycan glycosylation was only detected in 14 of
these. Seven patients had no indication of a dystroglyca-
nopathy based on immunostaining. It must be noted
that a standardised staining protocol was used for many,
but not all, of these patients. Conversely, an additional
15 patients of the remaining 209 for whom immuno-
staining was reported within the overall MYO-SEQ co-
hort had an α-dystroglycan deficiency or reduced
α-dystroglycan glycosylation, yet none of these har-
boured suspected pathogenic variants in any known dys-
troglycanopathy genes. In fact, nine of these patients had
suspected pathogenic variants in other neuromuscular
disease genes, leaving only six currently undiagnosed pa-
tients. Together, this suggests that (i) the detection of
changes in α-dystroglycan and its glycosylation may not
be entirely accurate and/or uniform across different clin-
ical sites, (ii) the glycosylation of α-dystroglycan may not
be the only affected dystroglycanopathy pathway, and
(iii) other dystroglycanopathies are most likely yet to be
characterised. Accordingly, the quantification of hypo-
glycosylation should not be the only gold standard for
diagnosing the diseases. We propose that a complemen-
tary approach including NGS should be used to aid the
correct diagnosis of these rare disease patients.
Our findings offer an expansion of the phenotypic
spectrum of dystroglycanopathies and suggest that an
unbiased NGS approach such as WES should be used
for a reliable diagnosis. Dolichol-phosphate-mannose
(DPM) synthase comprises the DPM1, DPM2 and
DPM3 subunits and is required for the synthesis of a
donor substrate (DPM) of glycosylation [42, 43]. A
homozygous DPM3 mutation (p.Leu85Ser) was first
identified in an 11-year-old female with a mild LGMD,
cardiomyopathy at 20 years of age and a stroke-like epi-
sode at 21 years of age [44]. Interestingly, our identifica-
tion of a patient with a homozygous DPM3 mutation
(p.Leu44Pro) is the first description of such a patient
without cardiomyopathy or central nervous system in-
volvement [24]. Moreover, we identified two siblings
with POMK mutations. Typically, patients with muta-
tions in this gene have displayed a severe phenotype ran-
ging from Walker-Warburg syndrome to LGMD with
cognitive impairment. Unlike a previously described pa-
tient with POMK compound heterozygous variants, the
siblings did not display a typical Walker-Warburg syn-
drome with cognitive impairments [45]. Finally, FKTN
mutations are commonly associated with Fukuyama con-
genital muscular dystrophy in Japan, which is
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characterised by hypotonia, muscle weakness, and cere-
bral and cerebellar cortical dysplasia [12]. Fewer patients
with LGMD caused by FKTN mutations have been re-
ported, and these usually have a milder phenotype of
proximal muscle weakness and no cognitive involvement
[46]. Our Caucasian patient, as expected, did not carry
the Japanese founder haplotype and displayed a slowly
progressive limb-girdle and axial myopathy. This com-
plements and enhances the current understanding of
diseases associated with FKTN mutations. Compound
heterozygous and homozygous mutations in ISPD have
been associated with a broad clinical spectrum ranging
from mild LGMD to a more severe Walker-Warburg
syndrome [47], with the mutations predicted to be dele-
terious to protein function. However, patient 14 has only
one frameshift variant that could result in a null allele and
disrupt ISPD function (p.Cys56ValfsTer60); the second
variant (p.Ser202Leu) is in an exon at the N terminal of
the gene that is present in only one transcript. This may
explain the observed milder phenotype of the patient.
We have observed that within our cohort, suspected
pathogenic mutations in POMT2 are the most common
cause of dystroglycanopathies. This was similarly ob-
served in a concentrated cohort of patients with
α-dystroglycan hypoglycosylation [29]. Crucially, 15 of
our 27 patients had suspected pathogenic variants in
genes that were omitted from the aforementioned study
(DPM3, FKRP, GMPPB, ISPD and POMK), indicating
that an unbiased approach must be sought to fully char-
acterise dystroglycanopathies. Indeed, even with a tar-
geted NGS methodology, many of the patients in our
MYO-SEQ cohort remain without a diagnosis. This sug-
gests that patients may harbour pathogenic variants in
genes with no currently known association to muscle
disease, including uncharacterised dystroglycanopathies.
It must be noted that rather than mutations in POMT2,
those in FKRP are widely considered to cause the com-
monest dystroglycanopathy in Europe, LGMD2I [48].
While our data do not reflect this exactly, the 30% of pa-
tients with FKRP mutations strongly support the high
prevalence of LGMD2I. A small n number, simple ascer-
tainment bias and the ease at which FKRP can be
sequenced in diagnostic work-ups—negating the need
for inclusion in MYO-SEQ in these patients—could be
responsible for these skewed data. Moreover, FKRP
typically has a lower coverage with exome sequencing,
meaning fewer LGMD2I patients might be detected
relative to those identified through Sanger sequencing.
Conclusions
Overall, dystroglycanopathies are a clinically and genet-
ically heterogeneous group of disorders, and as such, ac-
curate diagnoses are often difficult to achieve. We have
collected a unique group of 27 dystroglycanopathy
patients that offer an extended understanding of the
phenotypes at the milder end of the disease spectrum.
The disease group is highly diverse and complex, rein-
forced by the detection of variants in patients with an
atypical dystroglycanopathy phenotype. We present evi-
dence of the benefit of integrating WES into healthcare
systems in an effort to diagnose rare diseases more readily
and accurately. Further tests will now be required to
determine the mechanisms by which these proteins act
and to confirm the dysregulation of α-dystroglycan
glycosylation.
Additional file
Additional file 1: Clinical presentations and phenotypes of the 27
MYO-SEQ index cases with suspected pathogenic variants in genes
associated with dystroglycanopathies. Muscle pathology findings are
defined as a replacement of muscle with fat on T1-weighted axial images.
Radiology reports from referring centres are not standardised or quantitative.
FVC = forced vital capacity; LVEF = left ventricular ejection fraction; LVFS = left
ventricular fractional shortening; RNS = repetitive nerve stimulation.
No indications = immunostaining was performed but was not suggestive of
an α-DG deficiency. (XLSX 14 kb)
Abbreviations
CK: Creatine kinase; DAG1: Dystroglycan 1; DPM: Dolichol-phosphate-mannose;
ECM: Extracellular matrix; EGA: European Genome–phenome Archive;
EMG: Electromyography; FVC: Forced vital capacities; IHC: Immunohistochemistry;
LGMD: Limb-girdle muscular dystrophies; LVEF: Left ventricular ejection fraction;
LVFS: Left ventricular fractional shortening; NGS: Next-generation sequencing;
RNS: Repetitive nerve stimulation; WES: Whole-exome sequencing
Acknowledgements
We thank the patients for donating their tissue samples.
Funding
The MYO-SEQ project was supported by Sanofi Genzyme, Ultragenyx, LGMD2I
Research Fund, Samantha J Brazzo Foundation, LGMD2D Foundation, Kurt
+Peter Foundation, Muscular Dystrophy UK and Coalition to Cure Calpain 3.
Analysis performed by the Broad team was partially funded by the Center for
Mendelian Genomics (UM1 HG008900) grant from the National Human
Genome Research Institute. The funders of the study had no role in the study
design, data collection and analysis, decision to publish or preparation of the
manuscript.
Availability of data and materials
Linked genotype and phenotype data can be accessed through the European
Genome–phenome Archive (EGA; EGAS00001002069).
Authors’ contributions
KJ acquired, analysed and interpreted the data, prepared the manuscript for
publication and acquired funding. MB, AT, LP, LX, EV, TEM and ML acquired,
analysed and interpreted the data. PVdB, JV, NW, SN, SJO, AL, AKP, APC, ND,
CWP, SSK, JC, KGC, WDR, JB, MvdH, RFT, MZI, JBV, AH, HD and TW made
substantial contributions to the acquisition of data. VS was responsible for
the conception and design. VS and DGM acquired the funding and data.
All authors read, critically revised and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval (REC reference number 08/H0906/28) was granted by the
Newcastle and North Tyneside Research Ethics Committee. All patients provided
informed written consent to participate in the project.
Consent for publication
Not applicable.
Johnson et al. Skeletal Muscle  (2018) 8:23 Page 9 of 12
Competing interests
VS is or has been on advisory boards for Acceleron Pharma, Audentes
Therapeutics, Biogen, Biomarin, Bristol-Myer Squibb, Italfarmaco S.p.A., Nicox,
Pfizer, Sanofi Genzyme, Santhera Pharmaceuticals, Sarepta Therapeutics, Summit
Therapeutics, Tivorsan, TrophyNOD, and Wave Therapeutics. VS received speaker
honoraria from Sanofi Genzyme. VS has or had research collaborations with
Ultragenyx Pharmaceuticals and Sanofi Genzyme. All other authors declare that
they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1John Walton Muscular Dystrophy Research Centre, Institute of Genetic
Medicine, Newcastle University, Newcastle upon Tyne, UK. 2Newcastle
Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 3Neuromuscular
Reference Centre, University Hospital St-Luc, University of Louvain, Brussels,
Belgium. 4Copenhagen Neuromuscular Center, Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark. 5Iranian Center for Neurological
Research, Shariati Hospital, Tehran University of Medical Sciences, Tehran,
Iran. 6Department of Neurology, Medical University of Warsaw, Warsaw,
Poland. 7Ghent University Hospital, De Pintelaan 185, Ghent, Belgium.
8Paediatric Neurology Department, Hôpital Universitaire des Enfants Reine
Fabiola, ULB, Brussels, Belgium. 9The Folkhaelsan Department of Medical
Genetics, The Folkhaelsan Institute of Genetics, and the Department of
Medical and Clinical Genetics, University of Helsinki, Topeliuksenkatu 20,
Helsinki, Finland. 10Children’s Hospital, Helsinki University Hospital and
University of Helsinki, Helsinki, Finland. 11Unitat de Patología Neuromuscular,
Servei de Neurologia, Hospital Sant Joan de Déu, Barcelona, Spain.
12Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
13Laboratory for Muscle Diseases and Neuropathies, Department of
Neurosciences, University of Leuven (KU Leuven), Leuven, Belgium.
14Department of Neurology and Institute of Neuropathology, RWTH Aachen
University Hospital, Aachen, Germany. 15Neurogenetics Group, VIB-UA, Center
for Molecular Neurology, University of Antwerp, Antwerp, Belgium.
16Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of
Antwerp, Antwerp, Belgium. 17Neuromuscular Reference Centre, Department
of Neurology, Antwerp University Hospital, Antwerp, Belgium. 18Abteilung
Neuropädiatrie, Medizinische Fakultät Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany. 19Neuroscience Area, Biodonostia
Health Research Institute, San Sebastián, Spain. 20Center for Biomedical
Research in the Neurodegenerative Diseases (CIBERNED) Network, Instituto
Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain. 21Servicio
de Neurología, Hospital de Mendaro, Osakidetza, Mendaro, Spain.
22Department of Child Neurology, Justus-Liebig University, Gießen, Germany.
23Department of Neurology, Istanbul Faculty of Medicine, Istanbul University,
Istanbul, Turkey. 24The Robert Jones and Agnes Hunt Orthopaedic Hospital,
NHS Foundation Trust, Oswestry, UK. 25Analytic and Translational Genetics
Unit, Massachusetts General Hospital, Boston, MA, USA. 26Program in Medical
and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA,
USA.
Received: 25 April 2018 Accepted: 13 July 2018
References
1. Cohn RD, Henry MD, Michele DE, Barresi R, Saito F, Moore SA, Flanagan JD,
Skwarchuk MW, Robbins ME, Mendell JR, et al. Disruption of DAG1 in
differentiated skeletal muscle reveals a role for dystroglycan in muscle
regeneration. Cell. 2002;110:639–48.
2. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW,
Campbell KP. Primary structure of dystrophin-associated glycoproteins
linking dystrophin to the extracellular matrix. Nat. 1992;355:696–702.
3. Warner LE, DelloRusso C, Crawford RW, Rybakova IN, Patel JR, Ervasti JM,
Chamberlain JS. Expression of Dp260 in muscle tethers the actin
cytoskeleton to the dystrophin-glycoprotein complex and partially prevents
dystrophy. Hum Mol Genet. 2002;11:1095–105.
4. Godfrey C, Foley AR, Clement E, Muntoni F. Dystroglycanopathies: coming
into focus. Curr Opin Genet Dev. 2011;21:278–85.
5. Michele DE, Campbell KP. Dystrophin-glycoprotein complex: post-
translational processing and dystroglycan function. J Biol Chem. 2003;278:
15457–60.
6. Endo T. Dystroglycan glycosylation and its role in alpha-
dystroglycanopathies. Acta Myol. 2007;26:165–70.
7. Martin PT. Dystroglycan glycosylation and its role in matrix binding in
skeletal muscle. Glycobiology. 2003;13:55R–66R.
8. Astrea G, Pezzini I, Picillo E, Pasquariello R, Moro F, Ergoli M, D'Ambrosio P,
D'Amico A, Politano L, Santorelli FM. TMEM5-associated dystroglycanopathy
presenting with CMD and mild limb-girdle muscle involvement.
Neuromuscul Disord. 2016;26:459–61.
9. Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to
glycosylation defects. Neurotherapeutics. 2008;5:627–32.
10. Cylwik B, Lipartowska K, Chrostek L, Gruszewska E. Congenital disorders of
glycosylation. Part II. Defects of protein O-glycosylation. Acta Biochim Pol.
2013;60:361–8.
11. Teber S, Sezer T, Kafali M, Manzini MC, Konuk Yuksel B, Tekin M, Fitoz S, Walsh
CA, Deda G. Severe muscle-eye-brain disease is associated with a homozygous
mutation in the POMGnT1 gene. Eur J Paediatr Neurol. 2008;12:133–6.
12. Ishigaki K. Central nervous involvement in patients with Fukuyama
congenital muscular dystrophy. Brain Nerve. 2016;68:119–27.
13. Mitsuhashi S, Kang PB. Update on the genetics of limb girdle muscular
dystrophy. Semin Pediatr Neurol. 2012;19:211–8.
14. Brown SC, Torelli S, Brockington M, Yuva Y, Jimenez C, Feng L, Anderson L,
Ugo I, Kroger S, Bushby K, et al. Abnormalities in alpha-dystroglycan
expression in MDC1C and LGMD2I muscular dystrophies. Am J Pathol. 2004;
164:727–37.
15. Bouchet-Séraphin C, Vuillaumier-Barrot S, Seta N. Dystroglycanopathies:
about numerous genes involved in glycosylation of one single glycoprotein.
J Neuromuscul Dis. 2015;2:27–38.
16. Valencia CA, Husami A, Holle J, Johnson JA, Qian Y, Mathur A, Wei C,
Indugula SR, Zou F, Meng H, et al. Clinical impact and cost-effectiveness of
whole exome sequencing as a diagnostic tool: a pediatric center’s
experience. Front Pediatr. 2015;3:67.
17. Peric S, Glumac JN, Topf A, Savic-Pavicevic D, Phillips L, Johnson K, Cassop-
Thompson M, Xu L, Bertoli M, Lek M, et al. A novel recessive TTN founder
variant is a common cause of distal myopathy in the Serbian population.
Eur J Hum Genet. 2017;25:572–81.
18. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott
DR. ClinVar: public archive of relationships among sequence variation and
human phenotype. Nucleic Acids Res. 2014;42:D980–5.
19. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-
Luria AH, Ware JS, Hill AJ, Cummings BB, et al. Analysis of protein-coding
genetic variation in 60,706 humans. Nat. 2016;536:285–91.
20. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR. A method and server for predicting damaging
missense mutations. Nat Methods. 2010;7:248–9.
21. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat
Protoc. 2009;4:1073–81.
22. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods. 2014;11:361–2.
23. Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, Day IN,
Gaunt TR. Predicting the functional, molecular, and phenotypic
consequences of amino acid substitutions using hidden Markov models.
Hum Mutat. 2013;34:57–65.
24. Van den Bergh PYK, Sznajer Y, Van Parys V, van Tol W, Wevers RA, Lefeber DJ,
Xu L, Lek M, MacArthur DG, Johnson K, et al. A homozygous DPM3 mutation
in a patient with alpha-dystroglycan-related limb girdle muscular dystrophy.
Neuromuscul Disord. 2017; https://doi.org/10.1016/j.nmd.2017.07.006.
25. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA,
Ponting CP, Estournet B, Romero NB, Mercuri E, et al. Mutations in the
fukutin-related protein gene (FKRP) cause a form of congenital muscular
dystrophy with secondary laminin alpha2 deficiency and abnormal
glycosylation of alpha-dystroglycan. Am J Hum Genet. 2001;69:1198–209.
26. Hafner P, Bonati U, Fischmann A, Schneider J, Frank S, Morris-Rosendahl DJ,
Dumea A, Heinimann K, Fischer D. Skeletal muscle MRI of the lower limbs in
congenital muscular dystrophy patients with novel POMT1 and POMT2
mutations. Neuromuscul Disord. 2014;24:321–4.
27. Mercuri E, Brockington M, Straub V, Quijano-Roy S, Yuva Y, Herrmann R,
Brown SC, Torelli S, Dubowitz V, Blake DJ, et al. Phenotypic spectrum
Johnson et al. Skeletal Muscle  (2018) 8:23 Page 10 of 12
associated with mutations in the fukutin-related protein gene. Ann Neurol.
2003;53:537–42.
28. Mercuri E, Messina S, Bruno C, Mora M, Pegoraro E, Comi GP, D'Amico A,
Aiello C, Biancheri R, Berardinelli A, et al. Congenital muscular dystrophies
with defective glycosylation of dystroglycan: a population study. Neurol.
2009;72:1802–9.
29. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V,
Robb S, Quinlivan R, Feng L, et al. Refining genotype phenotype
correlations in muscular dystrophies with defective glycosylation of
dystroglycan. Brain. 2007;130:2725–35.
30. Carss KJ, Stevens E, Foley AR, Cirak S, Riemersma M, Torelli S, Hoischen A,
Willer T, van Scherpenzeel M, Moore SA, et al. Mutations in GDP-mannose
pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies
associated with hypoglycosylation of alpha-dystroglycan. Am J Hum Genet.
2013;93:29–41.
31. Belaya K, Rodriguez Cruz PM, Liu WW, Maxwell S, McGowan S, Farrugia ME,
Petty R, Walls TJ, Sedghi M, Basiri K, et al. Mutations in GMPPB cause
congenital myasthenic syndrome and bridge myasthenic disorders with
dystroglycanopathies. Brain. 2015;138:2493–504.
32. Strang-Karlsson S, Johnson K, Topf A, Xu L, Lek M, MacArthur DG, Casar-
Borota O, Williams M, Straub V, Wallgren-Pettersson C. A novel compound
heterozygous mutation in the POMK gene causing limb-girdle muscular
dystrophy-dystroglycanopathy in a sib pair. Neuromuscul Disord. 2018;
https://doi.org/10.1016/j.nmd.2018.04.012.
33. Wallace SE, Conta JH, Winder TL, Willer T, Eskuri JM, Haas R, Patterson K,
Campbell KP, Moore SA, Gospe SM Jr. A novel missense mutation in POMT1
modulates the severe congenital muscular dystrophy phenotype associated
with POMT1 nonsense mutations. Neuromuscul Disord. 2014;24:312–20.
34. Biancheri R, Falace A, Tessa A, Pedemonte M, Scapolan S, Cassandrini D,
Aiello C, Rossi A, Broda P, Zara F, et al. POMT2 gene mutation in limb-girdle
muscular dystrophy with inflammatory changes. Biochem Biophys Res
Commun. 2007;363:1033–7.
35. Yanagisawa A, Bouchet C, Van den Bergh PY, Cuisset JM, Viollet L, Leturcq F,
Romero NB, Quijano-Roy S, Fardeau M, Seta N, Guicheney P. New POMT2
mutations causing congenital muscular dystrophy: identification of a
founder mutation. Neurol. 2007;69:1254–60.
36. Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can
exome sequencing do for you? J Med Genet. 2011;48:580–9.
37. Farlow JL, Robak LA, Hetrick K, Bowling K, Boerwinkle E, Coban-Akdemir ZH,
Gambin T, Gibbs RA, Gu S, Jain P, et al. Whole-exome sequencing in familial
Parkinson disease. JAMA Neurol. 2016;73:68–75.
38. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ,
Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, et al. De novo
mutations revealed by whole-exome sequencing are strongly associated
with autism. Nat. 2012;485:237–41.
39. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe
JM, Dasu T, Tschannen MR, Veith RL, et al. Making a definitive diagnosis:
successful clinical application of whole exome sequencing in a child with
intractable inflammatory bowel disease. Genet Med. 2011;13:255–62.
40. van Reeuwijk J, Janssen M, van den Elzen C, Beltran-Valero de Bernabe D,
Sabatelli P, Merlini L, Boon M, Scheffer H, Brockington M, Muntoni F, et al.
POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-
Warburg syndrome. J Med Genet. 2005;42:907–12.
41. Jimenez-Mallebrera C, Torelli S, Feng L, Kim J, Godfrey C, Clement E, Mein R,
Abbs S, Brown SC, Campbell KP, et al. A comparative study of alpha-
dystroglycan glycosylation in dystroglycanopathies suggests that the
hypoglycosylation of alpha-dystroglycan does not consistently correlate
with clinical severity. Brain Pathol. 2009;19:596–611.
42. Maeda Y, Tanaka S, Hino J, Kangawa K, Kinoshita T. Human dolichol-
phosphate-mannose synthase consists of three subunits, DPM1, DPM2 and
DPM3. EMBO J. 2000;19:2475–82.
43. Schenk B, Fernandez F, Waechter CJ. The ins(ide) and out(side) of dolichyl
phosphate biosynthesis and recycling in the endoplasmic reticulum.
Glycobiology. 2001;11:61R–70R.
44. Lefeber DJ, Schonberger J, Morava E, Guillard M, Huyben KM, Verrijp K,
Grafakou O, Evangeliou A, Preijers FW, Manta P, et al. Deficiency of Dol-P-
Man synthase subunit DPM3 bridges the congenital disorders of
glycosylation with the dystroglycanopathies. Am J Hum Genet. 2009;85:
76–86.
45. Jae LT, Raaben M, Riemersma M, van Beusekom E, Blomen VA, Velds A,
Kerkhoven RM, Carette JE, Topaloglu H, Meinecke P, et al. Deciphering the
glycosylome of dystroglycanopathies using haploid screens for lassa virus
entry. Sci. 2013;340:479–83.
46. Pegoraro E, Hoffman EP. Limb-girdle muscular dystrophy overview. In:
Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, LJH B, Bird TD,
Ledbetter N, Mefford HC, RJH S, Stephens K, editors. GeneReviews(R).
Seattle: University of Washington; 1993-2018. 2000. [updated 2012 Aug 30].
https://www.ncbi.nlm.nih.gov/books/NBK1408/.
47. Willer T, Lee H, Lommel M, Yoshida-Moriguchi T, de Bernabe DB, Venzke D,
Cirak S, Schachter H, Vajsar J, Voit T, et al. ISPD loss-of-function mutations
disrupt dystroglycan O-mannosylation and cause Walker-Warburg
syndrome. Nat Genet. 2012;44:575–80.
48. Kanagawa M, Toda T. Muscular dystrophy with ribitol-phosphate deficiency:
a novel post-translational mechanism in dystroglycanopathy. J Neuromuscul
Dis. 2017;4:259–67.
49. McKusick VA. Mendelian Inheritance in Man and its online version, OMIM.
Am J Hum Genet. 2007;80:588–604.
50. Stevens E, Carss KJ, Cirak S, Foley AR, Torelli S, Willer T, Tambunan DE, Yau S,
Brodd L, Sewry CA, et al. Mutations in B3GALNT2 cause congenital muscular
dystrophy and hypoglycosylation of alpha-dystroglycan. Am J Hum Genet.
2013;92:354–65.
51. Buysse K, Riemersma M, Powell G, van Reeuwijk J, Chitayat D, Roscioli T,
Kamsteeg EJ, van den Elzen C, van Beusekom E, Blaser S, et al. Missense
mutations in beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause
Walker-Warburg syndrome. Hum Mol Genet. 2013;22:1746–54.
52. Geis T, Marquard K, Rodl T, Reihle C, Schirmer S, von Kalle T, Bornemann A,
Hehr U, Blankenburg M. Homozygous dystroglycan mutation associated
with a novel muscle-eye-brain disease-like phenotype with multicystic
leucodystrophy. Neurogenetics. 2013;14:205–13.
53. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, Kanagawa M, Beltran-Valero de
Bernabe D, Gundesli H, Willer T, Satz JS, Crawford RW, Burden SJ, et al. A
dystroglycan mutation associated with limb-girdle muscular dystrophy. N
Engl J Med. 2011;364:939–46.
54. Kranz C, Jungeblut C, Denecke J, Erlekotte A, Sohlbach C, Debus V, Kehl HG,
Harms E, Reith A, Reichel S, et al. A defect in dolichol phosphate
biosynthesis causes a new inherited disorder with death in early infancy.
Am J Hum Genet. 2007;80:433–40.
55. Kim S, Westphal V, Srikrishna G, Mehta DP, Peterson S, Filiano J, Karnes PS,
Patterson MC, Freeze HH. Dolichol phosphate mannose synthase (DPM1)
mutations define congenital disorder of glycosylation Ie (CDG-Ie). J Clin
Invest. 2000;105:191–8.
56. Barone R, Aiello C, Race V, Morava E, Foulquier F, Riemersma M, Passarelli C,
Concolino D, Carella M, Santorelli F, et al. DPM2-CDG: a muscular dystrophy-
dystroglycanopathy syndrome with severe epilepsy. Ann Neurol. 2012;72:550–8.
57. Beltran-Valero de Bernabe D, Voit T, Longman C, Steinbrecher A, Straub V,
Yuva Y, Herrmann R, Sperner J, Korenke C, Diesen C, et al. Mutations in the
FKRP gene can cause muscle-eye-brain disease and Walker-Warburg
syndrome. J Med Genet. 2004;41:e61.
58. de Bernabe DB, van Bokhoven H, van Beusekom E, Van den Akker W, Kant
S, Dobyns WB, Cormand B, Currier S, Hamel B, Talim B, et al. A homozygous
nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome
phenotype. J Med Genet. 2003;40:845–8.
59. Godfrey C, Escolar D, Brockington M, Clement EM, Mein R, Jimenez-
Mallebrera C, Torelli S, Feng L, Brown SC, Sewry CA, et al. Fukutin gene
mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol.
2006;60:603–10.
60. Tasca G, Moro F, Aiello C, Cassandrini D, Fiorillo C, Bertini E, Bruno C, Santorelli
FM, Ricci E. Limb-girdle muscular dystrophy with alpha-dystroglycan deficiency
and mutations in the ISPD gene. Neurol. 2013;80:963–5.
61. Longman C, Brockington M, Torelli S, Jimenez-Mallebrera C, Kennedy C,
Khalil N, Feng L, Saran RK, Voit T, Merlini L, et al. Mutations in the human
LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy
with severe mental retardation and abnormal glycosylation of alpha-
dystroglycan. Hum Mol Genet. 2003;12:2853–61.
62. Hehr U, Uyanik G, Gross C, Walter MC, Bohring A, Cohen M, Oehl-
Jaschkowitz B, Bird LM, Shamdeen GM, Bogdahn U, et al. Novel POMGnT1
mutations define broader phenotypic spectrum of muscle-eye-brain disease.
Neurogenetics. 2007;8:279–88.
63. Clement EM, Godfrey C, Tan J, Brockington M, Torelli S, Feng L, Brown SC,
Jimenez-Mallebrera C, Sewry CA, Longman C, et al. Mild POMGnT1
mutations underlie a novel limb-girdle muscular dystrophy variant. Arch
Neurol. 2008;65:137–41.
Johnson et al. Skeletal Muscle  (2018) 8:23 Page 11 of 12
64. Manzini MC, Tambunan DE, Hill RS, Yu TW, Maynard TM, Heinzen EL,
Shianna KV, Stevens CR, Partlow JN, Barry BJ, et al. Exome sequencing and
functional validation in zebrafish identify GTDC2 mutations as a cause of
Walker-Warburg syndrome. Am J Hum Genet. 2012;91:541–7.
65. von Renesse A, Petkova MV, Lutzkendorf S, Heinemeyer J, Gill E, Hubner C,
von Moers A, Stenzel W, Schuelke M. POMK mutation in a family with
congenital muscular dystrophy with merosin deficiency, hypomyelination,
mild hearing deficit and intellectual disability. J Med Genet. 2014;51:275–82.
66. Di Costanzo S, Balasubramanian A, Pond HL, Rozkalne A, Pantaleoni C,
Saredi S, Gupta VA, Sunu CM, Yu TW, Kang PB, et al. POMK mutations
disrupt muscle development leading to a spectrum of neuromuscular
presentations. Hum Mol Genet. 2014;23:5781–92.
67. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, Celli J, van Beusekom
E, van der Zwaag B, Kayserili H, Merlini L, Chitayat D, Dobyns WB, et al.
Mutations in the O-mannosyltransferase gene POMT1 give rise to the
severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum
Genet. 2002;71:1033–43.
68. van Reeuwijk J, Maugenre S, van den Elzen C, Verrips A, Bertini E, Muntoni
F, Merlini L, Scheffer H, Brunner HG, Guicheney P, van Bokhoven H. The
expanding phenotype of POMT1 mutations: from Walker-Warburg
syndrome to congenital muscular dystrophy, microcephaly, and mental
retardation. Hum Mutat. 2006;27:453–9.
69. Balci B, Uyanik G, Dincer P, Gross C, Willer T, Talim B, Haliloglu G, Kale G,
Hehr U, Winkler J, Topaloglu H. An autosomal recessive limb girdle
muscular dystrophy (LGMD2) with mild mental retardation is allelic to
Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1
gene. Neuromuscul Disord. 2005;15:271–5.
Johnson et al. Skeletal Muscle  (2018) 8:23 Page 12 of 12
